Atrial septal defect video showing percutaneous repair: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
[[Atrial septal defect percutaneous|percutaneous closure]] closure of [[atrial septal defect]], currently is only approved for [[Ostium secundum atrial septal defect|Secundum defects]]. Prior to the procedure, the patient is started on [[antiplatelet]] therapy for 6 months, to prevent thrombus formation. [[Transesophageal echocardiography]] used for determining the device size, position, and deployment | |||
==Pre-surgical considerations== | ==Pre-surgical considerations== | ||
Revision as of 00:58, 12 September 2011
|
Atrial Septal Defect Microchapters | |
|
Treatment | |
|---|---|
|
Surgery | |
|
| |
|
Special Scenarios | |
|
Case Studies | |
|
Atrial septal defect video showing percutaneous repair On the Web | |
|
American Roentgen Ray Society Images of Atrial septal defect video showing percutaneous repair | |
|
FDA on Atrial septal defect video showing percutaneous repair | |
|
CDC on Atrial septal defect video showing percutaneous repair | |
|
Atrial septal defect video showing percutaneous repair in the news | |
|
Blogs on Atrial septal defect video showing percutaneous repair | |
|
Risk calculators and risk factors for Atrial septal defect video showing percutaneous repair | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3] Assistant Editor(s)-In-Chief: Kristin Feeney, B.S. [4]
Overview
percutaneous closure closure of atrial septal defect, currently is only approved for Secundum defects. Prior to the procedure, the patient is started on antiplatelet therapy for 6 months, to prevent thrombus formation. Transesophageal echocardiography used for determining the device size, position, and deployment
Pre-surgical considerations
1) Prior to undergoing percutaneous closure, eligible atrial septal defect patients must undergo pharmacologic preparation therapy.
2) Most therapy regimens include antiplatelet drugs such as aspirin or clopidogrel for a minimum of six months to protect patients against thrombus formation.
3) Secundum defects are assessed via echocardiographic monitoring to determine the anatomic viability of percutaneous closure.
4) The ideal secundum defect is less than 30mm in diameter with an accompanying rim of tissue around the defect of at least 5mm.
5) The rim of tissue serves to prevent impingement upon the superior vena cava (SVC), inferior vena cava (IVC), as well as the tricuspid or mitral valves.[1]
Per-cutaneous closure
The salient feature of the percutaneous closure are-
1) Device is placed via femoral vein
2) Best results are for centrally located secundum defects.
3) Static diameter of the defect is assessed by using transesophageal echocardiography
4) Transesophageal echocardiography used for determining the device size, position, and deployment
5) A 'stop-flow' technique is used to select the proper diameter of the device
6) In the stop flow technique, the sizing balloon is inflated until no flow is visible through the defect using transesophageal echocardiography.
7) The margins of the defect must be ≤5 mm to accommodate the edges of the device.
<youtube v=Gros-u7YCTk/>